AureoGen Biosciences is developing a novel drug for the treatment of systemic fungal infections, a $6 billion market with an empty development pipeline and an immediate unmet need for new and better therapeutics. AureoGen has generated novel, well tolerated, efficacious, broad spectrum derivatives (all NCEs), of the antifungal compound aureobasidin A, that have a novel mode of action and the potential be true first-in-class therapeutics.